Amneal and Zambon Secure Key EU Nod for Parkinson’s Treatment Hopledo
Event summary
- The CHMP issued a positive opinion for Hopledo® (IPX203) in treating Parkinson’s disease with motor fluctuations.
- Phase 3 RISE-PD trial data showed significant improvement in 'Good ON' time compared to immediate-release levodopa/carbidopa.
- Hopledo®, already marketed as CREXONT® in the U.S., could launch in Europe by October 2026 if approved by the European Commission.
The big picture
The positive CHMP opinion for Hopledo® underscores the growing demand for advanced Parkinson’s treatments in Europe, where over one million patients face motor fluctuations. Amneal’s partnership with Zambon strengthens its global footprint in neurology, building on CREXONT®’s established U.S. presence. The approval could position Hopledo® as a key competitor in the fragmented Parkinson’s market, particularly for patients needing sustained symptom control.
What we're watching
- Regulatory Approval
- Whether the European Commission will finalize approval for Hopledo® by October 2026.
- Market Penetration
- The pace at which Zambon and Amneal can introduce Hopledo® across Europe, given the high unmet need in Parkinson’s treatment.
- Commercial Strategy
- How Amneal leverages its U.S. experience with CREXONT® to support Hopledo®’s European launch and expansion.